Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Open accessThe DOI matches its Crossref record; 230 of the 235 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and have long been considered incurable. Following the successful development of a gene augmentation therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different therapeutic approaches are currently being developed, in particular a large variety of molecular therapies. These are depending on the severity of the retinal degeneration, knowledge of the pathophysiological mechanism underlying each subtype of IRD, and the therapeutic target molecule. DNA therapies include approaches such as gene augmentation therapy, genome editing and optogenetics. For some genetic subtypes of IRD, RNA therapies and compound therapies have also shown considerable therapeutic potential. In this review, we summarize the current state-of-the-art of various therapeutic approaches, including the pros and cons of each strategy, and outline the future challenges that lie ahead in the combat against IRDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, another large gene, CEP290, can be rescued on the mRNA level by antisense oligonucleotides (AONs; QR-110 for Leber congenital amaurosis (LCA), with CEP290; QR-421a for LCA with USH2A) [19].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–230 of 230
Bogéa, T. H., Wen, R. H., & Moritz, O. L. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-16799 · Cited by 38
AAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models
Stieger, K., Lheriteau, E., Moullier, P., & Rolling, F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.206 · Cited by 37
Applications of antisense oligonucleotides for the treatment of inherited retinal diseases
Collin, R. W. J., & Garanto, A. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000363 · Cited by 37
Self-citationDuijkers, L., van den Born, L. I., Neidhardt, J., Bax, N. M., Pierrache, L. H. M., Klevering, B. J., Collin, R. W. J., & Garanto, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030753 · Cited by 37
Self-citationTorriano, S., Erkilic, N., Baux, D., Cereso, N., DeLuca, V. J., Meunier, I., Moosajee, M., Roux, A., Hamel, C., & Kalatzis, V. (2018) · Scientific Reports · doi:10.1038/s41598-018-26481-7 · Cited by 36
Sarkar, H., Mitsios, A., Smart, M. J. K., Skinner, J. S., Welch, A. A., Kalatzis, V., Coffey, P. J., Dubis, A. M., Webster, A. R., & Moosajee, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz028 · Cited by 34
Dual AAV Vectors for Stargardt Disease
Trapani, I. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_11 · Cited by 33
The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases.
Peddle, C. F., & MacLaren, R. E. (2017) · PubMed Central · Cited by 33
Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA
Dooley, S. J., McDougald, D. S., Fisher, K. J., Bennicelli, J. L., Mitchell, L. G., & Bennett, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.014 · Cited by 32
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30 · cited 9×
“Both vectors showed promising results in mice but in NHPs, either subretinal or intravitreal delivery did not allow to transduce all target cells within the retina.”
BackgroundInfluentialGenomic organization of the mouse Msh4 gene producing bicistronic, chimeric and antisense mRNA
Hirano, M., & Noda, T. (2004) · Gene · doi:10.1016/j.gene.2004.08.016 · Cited by 29
Gene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Barny, I., Perrault, I., Michel, C., Goudin, N., Defoort‐Dhellemmes, S., Ghazi, I., Kaplan, J., Rozet, J., & Gérard, X. (2019) · Genes · doi:10.3390/genes10050368 · Cited by 28
Naessens, S., Ruysschaert, L., Lefever, S., Coppieters, F., & Baere, E. B. W. D. (2019) · Genes · doi:10.3390/genes10050363 · Cited by 27
Bacchi, N., Casarosa, S., & Denti, M. A. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14544 · Cited by 26
Boyer, D., Cowen, S. J., Danis, R. P., Jg, D., Fish, R. H., Da, G., Jaffe, G. J., Jp, L., Lieberman, R., Belfort, R., et al. (2002) · UCL Discovery (University College London) · Cited by 26
Tao, Y., Dong, X., Lu, X., Qu, Y., Wang, C., Peng, G.-H., & Zhang, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109021 · Cited by 26
Engineered Zinc Finger Nuclease–Mediated Homologous Recombination of the Human Rhodopsin Gene
Greenwald, D. L., Cashman, S. M., & Kumar‐Singh, R. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5781 · Cited by 25
Gene Delivery to the Retina Using Lentiviral Vectors
Greenberg, K. P., Lee, E. S., Schaffer, D. V., & Flannery, J. G. (2007) · Springer eBooks · doi:10.1007/0-387-32442-9_36 · Cited by 24
Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina
Li, F., Hung, S. S. C., Mohd Khalid, M. K. N., Wang, J.-H., Chrysostomou, V., Wong, V. H. Y., Singh, V., Wing, K., Tu, L., Bender, J. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.021 · Cited by 24
Zelinka, C. P., Sotolongo-Lopez, M., & Fadool, J. M. (2018) · PubMed Central · Cited by 23
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
Identification and Analysis of Genes Associated with Inherited Retinal Diseases
Khan, M., Fadaie, Z., Cornelis, S. S., Cremers, F. P. M., & Roosing, S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8669-9_1 · Cited by 18
Tauroursodeoxycholic acid binds to the G-protein site on light activated rhodopsin
Lobysheva, E., Taylor, C. M., Marshall, G. R., & Kisselev, O. G. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.02.015 · Cited by 17
Faber, S., & Roepman, R. (2019) · Genes · doi:10.3390/genes10080557 · Cited by 16
Active Aspiration of Suprachoroidal Hemorrhage Using a Guarded Needle
Mandelcorn, E. D., Kitchens, J. W., Callaway, N. F., & Moshfeghi, D. M. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20140306-09 · Cited by 14
Yau, E. H., Butler, M. C., & Sullivan, J. M. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.05.020 · Cited by 13
Essential function of NHE8 in mouse retina demonstrated by AAV-mediated CRISPR/Cas9 knockdown
Xia, C.-H., Ferguson, I., Li, M., Kim, A., Onishi, A., Li, L., Su, B., & Gong, X. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.06.026 · Cited by 12
Targeting the Proteostasis Network in Rhodopsin Retinitis Pigmentosa
Parfitt, D. A., & Cheetham, M. E. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17121-0_64 · Cited by 8
Patient-centered advancements in cataract surgery
Gali, H. E., & Afshari, N. A. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000341 · Cited by 3
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“…another subtype of inherited retinal disease that is caused by bi-allelic mutations in RPE65, has provided hope for many visually impaired individuals, and is paralleled by the development of similar therapeutic strategies for other genes underlying these disorders (Vazquez-Dominguez et al., 2019).”
BackgroundSelf-citationPontikos, N., Arno, G., Jurkute, N., Schiff, E., Ba-Abbad, R., Malka, S., Gimenez, A., Georgiou, M., Wright, G., Armengol, M., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.008 · Cited by 254
“Adenoassociated viruses have been a vector of choice for ocular gene therapy trials, targeting retinal cells with relatively low immunogenicity, but their capacity is limited.(5) We explored transcript lengths and relationships with numbers of families affected.”
BackgroundInfluentialHerrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
“Luxturna has established the safety and efficacy of gene augmentation via subretinal delivery, and, now, many different AAV gene therapies are under preclinical and/or clinical development (7, 8).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
Self-citation
Metadata
- Authors
- Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J.
- Affiliations
- Radboud University Nijmegen (NL)
- Corresponding author
- Garanto, Alejandro
- Collin, Rob W. J.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-08-28
- Volume
- 10
- Issue
- 9
- Pages
- 654
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6770110
- OpenAlex
- W2971284229
- Cited by
- 80
- References
- 235
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 19 · 2021: 24 · 2020: 11 · 2019: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (PPA-0517-0717-RAD)
- UitZicht (2015-31, 2018-21)
- ZonMw (Off Road 91215203)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- inherited retinal disease, gene therapy, gene augmentation therapy, RPE65, genome editing, optogenetics, RNA therapeutics, retinal degeneration, molecular therapy
- MeSH terms
- Clinical Trials as Topic, Humans, Retinal Degeneration, Genetic Therapy, Gene Transfer Techniques, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.